Gastrointestinal Microbiota and Breast Cancer Chemotherapy Interactions: A Systematic Review

Csendes, Denise; Gutlapalli, Sai Dheeraj; Prakash, Keerthana; Swarnakari, Kiran Maee; Bai, Meena; Manoharan, Mohana Priya; Raja, Rabab; Jamil, Aneeque; Desai, Aditya; Desai, Darshi M; Khan, Safeera

doi:10.7759/cureus.31648

Cited by 4 publications

(3 citation statements)

References 33 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human digestive system contains approximately 100 trillion bacteria. A recent systematic review of nine studies reveals some intriguing trends 42 . A high alpha diversity, which reflects a high diversity in the microbiome and is regarded as an indicator of good gut health, is associated with better responses to neoadjuvant chemotherapy, whereas low alpha diversity is associated with resistance.…”

Section: Gastrointestinal Microbiotamentioning

confidence: 99%

The Current and Evolving Landscape of Breast Cancer Prediction and Prognosis

Sharma

2023

MRAJ

View full text Add to dashboard Cite

The biological behaviour of breast cancer is remarkably heterogeneous and it is essential to have tools which can provide the necessary risk stratification to plan clinical management. Breast cancer prediction and prognosis needs to be holistic, and account for multiple levels of organisation. The histological classification and grading of the tumour itself presents valuable predictive and prognostic information. Hormone receptor status remains a mainstay, but roles may emerge for assessment of the intrinsic molecular subtype, for a molecular subclassification of triple negative carcinomas, and for whole genome sequencing. The recent discovery that antibody drug conjugates are effective in patients with weak HER-2 protein expression has led to the definition of the HER-2 low group. There has been a proliferation in predictive and prognostic models, numbering over 900, but the majority are at high risk of bias and tend to perform less well when applied to populations beyond the development cohort. The Nottingham Prognostic Index is a notable exception. Of the molecular risk stratification tools currently available, Oncotype Dx is the most widely recommended and used, but the question as to which test is superior remains unanswerable with current data. There is growing interest in omics-based approaches from which a number of biomarkers are being developed. It is well established that the microenvironment of the tumour is key to the tumour’s behaviour. Some components contain and destroy the cancer, whereas others are co-opted by the tumour and aid in its progression; the current evidence is reviewed, including the current status of tumour infiltrating lymphocyte assessment and immune checkpoint inhibition in breast cancer. The use of the liquid biopsy to achieve early detection of tumours and to manage tumour evolution is receiving intense attention; approaches include circulating tumour cells and circulating tumour DNA. Specific assessment of tumour giant cells may also provide the ability to anticipate tumour evolution. The influence of the gut microbiome on breast cancer is an intriguing development which requires further intensive study. There is a paucity of biomarkers in the setting of hereditary breast cancer. The use of polygenic risk scores in this setting is an interesting development requiring further study. The greatest challenge of all is to pull from such complexity key decision nodes that are clear enough to guide treatment decisions without losing the depth and richness of the information that underlies them. Seeking and finding this balance has been and will continue to be the holy grail of all endeavours in this field.

show abstract

Section: Gastrointestinal Microbiotamentioning

confidence: 99%

The Current and Evolving Landscape of Breast Cancer Prediction and Prognosis

Sharma

2023

MRAJ

View full text Add to dashboard Cite

show abstract

“…The gut microbiota dysbiosis (imbalance) may lead to the development of breast cancer through the crosstalk among microbiota and both endogenous hormones and estrogen-like compounds might synergize to provide protection from disease but also to increase the risk of developing hormone-related diseases [8][9][10][11] . Besides, diversity and speci c microbiota were linked to chemotherapy response as well as prognosis in breast cancer patients 12 . Microbiota diversity was also predictive of side effects such as neurological symptoms, weight gain, and constipation.…”

Section: Introductionmentioning

confidence: 99%

Relationship of Distress and Quality of Life with Gut Microbiome composition in Newly Diagnosed Breast Cancer Patients: a prospective, observational study

Lee

Yang

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

There is little research about the stress, quality of life (QOL) and gut microbiota in newly diagnosed breast cancer patients. We sought to determine the relationship of distress scale and FACT-B different domain and fecal microbial composition among newly diagnosed breast cancer patients. Total 82 newly diagnosed breast cancer patients were enrolled in this prospective, observational study. The mean score of the FACT-B was 104.5 (SD, 19.76). The mean DT score was 4.43, with 53.7% (44/82) of the patients reporting moderate to severe distress (score 5 or above). Several associations between distress, FACT-B different domain and microbial taxa were observed among this sample of breast cancer patients. Specifically, Alcaligenaceae and Sutterella were significantly more abundant in individuals with higher scores on the DT scale at the family and genus level, respectively (p = 0.017), while Streptococcaceae (p = 0.028) at the family level and Streptococcus (p = 0.023) at the genus level were significantly more abundant in individuals with lower scores on the DT scale. This study defines the relationships among stress, QOL and gut microbiota in newly diagnosed breast cancer patients and provides many useful information to find potential probiotics for decreasing stress and improving QOL in breast cancer patients.

show abstract

“…The gut microbiota dysbiosis (imbalance) may lead to the development of breast cancer through the crosstalk among microbiota and both endogenous hormones and estrogen-like compounds might synergize to provide protection from disease but also to increase the risk of developing hormone-related diseases 8 – 11 . Besides, diversity and specific microbiota were linked to chemotherapy response as well as prognosis in breast cancer patients 12 . Microbiota diversity was also predictive of side effects such as neurological symptoms, weight gain, and constipation.…”

Section: Introductionmentioning

confidence: 99%

Unraveling the connections between gut microbiota, stress, and quality of life for holistic care in newly diagnosed breast cancer patients

Lee,

Yang,

Liu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

There is little research about the stress, quality of life (QOL) and gut microbiota in newly diagnosed breast cancer patients. In this study addressing the dearth of research on stress, quality of life (QOL), and gut microbiota in newly diagnosed breast cancer patients, 82 individuals were prospectively observed. Utilizing the Functional Assessment of Chronic Illness Therapy (FACT)-Breast questionnaire to assess health-related quality of life (HRQOL) and the Distress Thermometer (DT) to gauge distress levels, the findings revealed a mean FACT-B score of 104.5, underscoring HRQOL's varied impact. Significantly, 53.7% reported moderate to severe distress, with a mean DT score of 4.43. Further exploration uncovered compelling links between distress levels, FACT-B domains, and microbial composition. Notably, Alcaligenaceae and Sutterella were more abundant in individuals with higher DT scores at the family and genus levels (p = 0.017), while Streptococcaceae at the family level and Streptococcus at the genus level were prevalent in those with lower DT scores (p = 0.028 and p = 0.023, respectively). This study illuminates the intricate interplay of stress, QOL, and gut microbiota in newly diagnosed breast cancer patients, offering valuable insights for potential interventions of biomarker or probiotics aimed at alleviating stress and enhancing QOL in this patient cohort.

show abstract

Gastrointestinal Microbiota and Breast Cancer Chemotherapy Interactions: A Systematic Review

Cited by 4 publications

References 33 publications

The Current and Evolving Landscape of Breast Cancer Prediction and Prognosis

The Current and Evolving Landscape of Breast Cancer Prediction and Prognosis

Relationship of Distress and Quality of Life with Gut Microbiome composition in Newly Diagnosed Breast Cancer Patients: a prospective, observational study

Unraveling the connections between gut microbiota, stress, and quality of life for holistic care in newly diagnosed breast cancer patients

Contact Info

Product

Resources

About